GTC Biotherapeutics (fka GTCB)

[ThomasS]

Since they are "preserving" the value of ATRYN for the DIC indication re HD pricing, this also necessarily implies that total ATRYN sales would be higher than expected for all sales, correct? (Assuming all EU pricing follows UK suite)

"And remember the pricing can vary from country to country in the European Union. LEO is pursuing a strategy to preserve the value of the subsequent DIC indication. [In other words, ATryn will be priced higher than it would if it were intended to be only a treatment for hereditary deficiency.]"